{"product_id":"skye-ansoff-analysis","title":"(SKYE) Skye Bioscience, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Expansion Decisions with the Full Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Skye Bioscience, Inc. Ansoff Matrix Analysis shows how the company can grow via market penetration, market development, product development, and diversification and is useful for strategy, investing, or planning; the page contains a real preview\/sample of the analysis so you can assess style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSBI-100 Phase I glaucoma and ocular hypertension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s clearest market penetration play is to deepen SBI-100 in the same lead use case: Phase I glaucoma and ocular hypertension. That matters because glaucoma affects about 80 million people worldwide, including roughly 11 million with bilateral blindness, so even small gains in this niche can matter. By building more evidence in the exact ophthalmology market it is targeting first, Skye Bioscience can improve clinician trust and future adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntraocular pressure reduction data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntraocular pressure is the main market-penetration lever for Skye Bioscience, Inc., because glaucoma and ocular hypertension are judged by pressure control. Clinically meaningful IOP drops should be the clearest proof point for share gains, and stronger readouts would help separate Skye Bioscience, Inc. from incumbent therapies. In a market where even small, durable millimeter-of-mercury reductions can shift prescribing, this endpoint is the key test.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology specialist focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience can win market penetration by keeping its lead asset aimed at glaucoma clinicians, the core eye-care specialists who already manage a disease affecting over 80 million people worldwide.\u003c\/p\u003e\n\u003cp\u003eThat tight focus keeps the message clinically relevant, supports specialist education, and reduces noise as the company advances development.\u003c\/p\u003e\n\u003cp\u003eIn a niche where each prescribing decision is highly evidence-led, a narrow ophthalmology focus can deepen trust and speed adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-stage cannabinoid differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience’s cannabinoid platform gives SBI-100 a clear scientific angle in glaucoma and ocular hypertension, where the global patient pool is still large and treatment options are crowded. That matters at clinical stage: with no commercial scale yet, differentiation is the main way to win physician attention and trial interest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCB1-based story supports clear positioning\u003c\/li\u003e\n\u003cli\u003eTargets a large, chronic eye-care market\u003c\/li\u003e\n\u003cli\u003eDifferentiation beats scale at this stage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSan Diego-based lead program execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSan Diego-based lead program execution is a clear market penetration move for Skye Bioscience, Inc. because it keeps capital, staff, and clinical attention on the highest-value current market instead of spreading thin. For a small biotech, depth in one ophthalmic segment is usually more practical than broad commercial reach.\u003c\/p\u003e\n\u003cp\u003eThe company’s San Diego base supports tight oversight of ophthalmic R and D and faster execution on the lead program. This fits penetration strategy: win more share in the current therapeutic niche before widening the pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocuses resources on one lead asset\u003c\/li\u003e\n\u003cli\u003eSupports ophthalmic R and D depth\u003c\/li\u003e\n\u003cli\u003eImproves execution in the current market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Targets a Massive Glaucoma Market with SBI-100\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s market penetration hinges on SBI-100 in glaucoma and ocular hypertension, where about 80 million people live with glaucoma worldwide and IOP remains the core efficacy measure. Deeper data in the same niche can sharpen clinician trust, support specialist adoption, and improve positioning versus entrenched eye-drop therapies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal glaucoma patients\u003c\/td\u003e\n\u003ctd\u003e~80 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey endpoint\u003c\/td\u003e\n\u003ctd\u003eIOP reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead focus\u003c\/td\u003e\n\u003ctd\u003eSBI-100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Skye Bioscience, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Skye Bioscience Ansoff Matrix to clarify growth options and ease strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that validate each Ansoff growth path for Skye Bioscience, speeding due diligence and traceable strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader ophthalmology reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.'s ophthalmic focus can move beyond one niche by taking the same cannabinoid platform into more eye-care settings and broader ophthalmology audiences. WHO says at least 2.2 billion people have near or distance vision impairment, so the addressable pool is wide. That can widen future access without changing the core product idea.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. is still clinical-stage, with no product revenue in 2025, so SBI-100’s next growth step is likely geographic expansion after stronger trial data. That fits market development because an ophthalmic therapy can move into new regions only after efficacy, safety, and regulatory files are ready. If development stays on track, the company can build a non-U.S. launch path before full commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRebranded Skye Bioscience identity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s January 2021 rebrand from Emerald Bioscience gave the company a cleaner identity that is easier for investors, partners, and ophthalmology stakeholders to remember. That matters in market development because a sharper brand can support expansion around the same lead asset story, which has been central as the company advanced through 2025. A clearer name also helps reduce friction when entering adjacent investor and clinical markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOcular hypertension patient expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular hypertension is a market development target for Skye Bioscience, Inc. because SBI-100 already spans both glaucoma and ocular hypertension, so the core asset stays the same while the addressable pool grows. Glaucoma affected about 76 million people in 2020 and is projected to reach 111.8 million by 2040; ocular hypertension adds a larger earlier-stage population.\u003c\/p\u003e\n\u003cp\u003eThis matters because ocular hypertension often precedes glaucoma, and studies show roughly 3% to 4% of adults over 40 have it, depending on the population. That lets Skye Bioscience, Inc. widen demand around one therapy area without changing the product thesis.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame candidate, broader patient base\u003c\/li\u003e\n\u003cli\u003eTargets early and later disease use\u003c\/li\u003e\n\u003cli\u003eSupports demand expansion, not redesign\u003c\/li\u003e\n\u003cli\u003eBuilds around a large eye-care market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty eye-care network access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty eye-care network access is Skye Bioscience, Inc.'s market development play: keep the product unchanged, but widen reach from a tight investigator base into more ophthalmology clinics, trial centers, and specialist practices.\u003c\/p\u003e\n\u003cp\u003eThat shifts adoption from one site type to a broader referral web, which can lift screening flow, site diversity, and trial execution speed. For eye-disease biotech, access is often won through specialist relationships, not just data.\u003c\/p\u003e\n\u003cp\u003eIt also reduces dependence on a few centers and helps scale into larger patient pools without changing the core asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeep product constant\u003c\/li\u003e\n\u003cli\u003eExpand specialist access\u003c\/li\u003e\n\u003cli\u003eAdd more trial sites\u003c\/li\u003e\n\u003cli\u003eBroaden referral channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Bets on Bigger Eye Disease Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.’s market development play is to keep SBI-100 unchanged and expand into bigger ophthalmology segments and geographies after stronger data. With 2025 revenue at $0, the near-term growth path is wider clinical and specialist access, not sales. Ocular hypertension adds a larger early-stage pool to glaucoma’s addressable market. WHO still cites 2.2 billion people with vision impairment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\/2026 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO vision impairment\u003c\/td\u003e\n\u003ctd\u003e2.2 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma cases\u003c\/td\u003e\n\u003ctd\u003e76 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2040 glaucoma forecast\u003c\/td\u003e\n\u003ctd\u003e111.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSkye Bioscience, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report on Skye Bioscience, Inc., covering market penetration, product development, market development, and diversification strategies with actionable insights. Purchase unlocks the complete, editable file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSBI-100 Phase I to later-stage advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.’s main product-development move is to push SBI-100 beyond Phase I and into later-stage testing, the key biotech step from proof of safety to proof of efficacy. That shift would lift the ophthalmic program’s value because each phase advance lowers clinical risk and can widen partner interest and deal terms. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSBI-200 preclinical progression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSBI-200 is already in preclinical work, so it gives Skye Bioscience, Inc. a second product path in the same ophthalmic lane. Moving it toward clinical readiness would broaden the pipeline beyond the lead program and raise the asset count from one to two. That kind of follow-on development fits an Ansoff product-development move: same market focus, new internal pipeline depth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple eye-disease indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSBI-200 is being developed across uveitis, dry eye disease, macular degeneration, and diabetic retinopathy, giving Skye Bioscience, Inc. a wider ophthalmology menu inside one therapeutic lane. The global retinal and ocular-disease burden is large: diabetic retinopathy affects about 1 in 3 people with diabetes, and dry eye disease is one of the most common eye complaints in adults. That breadth supports product development, not market expansion into new industries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCannabinoid-based ophthalmic pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience’s cannabinoid platform makes product development a pipeline play, not a single-asset bet. SBI-100 is the lead eye-disease program, and the same science can feed follow-on ophthalmic candidates if the first readouts de-risk the biology.\u003c\/p\u003e\n\u003cp\u003eThat matters because ophthalmology is a large, chronic-use market: glaucoma affects about 80 million people worldwide, so even one effective cannabinoid eye drug could support several shots on goal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne platform can yield multiple eye-drug assets\u003c\/li\u003e\n\u003cli\u003eSBI-100 is the lead proof point\u003c\/li\u003e\n\u003cli\u003eGlaucoma’s global base is ~80 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLead-and-follow-on asset structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. uses a lead-and-follow-on asset structure: one lead candidate, nimacimab, plus an earlier-stage follow-on program. That is a textbook product-development setup for a small biopharma company, because it keeps pipeline continuity if one asset moves slower or needs more capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne lead asset, one backup asset\u003c\/li\u003e\n\u003cli\u003eReduces single-program risk\u003c\/li\u003e\n\u003cli\u003eKeeps development moving\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Deepens Ophthalmology Pipeline with SBI-100 and SBI-200\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. is using product development to move SBI-100 from Phase I into later-stage proof of efficacy, which should lift value if results hold. SBI-200 adds a second ophthalmology path and broadens the pipeline. This is a same-market, new-asset move, not market expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBI-100\u003c\/td\u003e\n\u003ctd\u003ePhase I+\u003c\/td\u003e\n\u003ctd\u003eLead de-risking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBI-200\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eFollow-on depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaucoma to uveitis expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSBI-200 moves Skye Bioscience, Inc. beyond pressure-driven glaucoma into inflammatory eye disease, so it is classic diversification: a new product concept in a different ophthalmic submarket. That lowers reliance on one disease area and can spread clinical and commercial risk. Uveitis affects about 50,000 people in the United States each year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDry eye syndrome entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDry eye syndrome gives Skye Bioscience, Inc. a second ophthalmology path in the SBI-200 program, beyond glaucoma and ocular hypertension. Dry eye affects about 16 million U.S. adults, so even a modest share can widen the addressable market. This move spreads clinical risk across a different use case and can support future revenue optionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacular degeneration opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacular degeneration opens Skye Bioscience, Inc. to a much larger retinal market beyond glaucoma: age-related macular degeneration affects about 20 million people in the U.S. and nearly 200 million worldwide. Adding it to SBI-200 shows diversification through a new product aimed at a new eye-disease need. That can widen the company’s clinical pipeline and reduce dependence on one indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiabetic retinopathy program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiabetic retinopathy puts Skye Bioscience, Inc. into a new eye-disease market and a new patient pool, so it fits the Diversification move in the Ansoff Matrix. With 537 million adults living with diabetes worldwide in 2021 and about one-third at risk of diabetic retinopathy, the addressable pool is large and still growing. \u003c\/p\u003e\n\u003cp\u003eThis would stretch the pipeline beyond its core focus and lower reliance on a single disease area. That mix can improve strategic optionality if the program shows clinical traction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew disease area\u003c\/li\u003e\n\u003cli\u003eNew patient population\u003c\/li\u003e\n\u003cli\u003eBroadens pipeline risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-disease ophthalmology platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience is moving from a single lead asset into a multi-indication ophthalmology platform, and that is its clearest diversification step. Instead of relying on one eye-disease path, the same platform can support growth across several ocular markets, which lowers pipeline concentration risk and broadens the shot at clinical success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpreads risk across eye diseases\u003c\/li\u003e\n\u003cli\u003eCreates multiple growth paths\u003c\/li\u003e\n\u003cli\u003eReduces single-asset dependence\u003c\/li\u003e\n\u003cli\u003eSupports platform-led expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Expands SBI-200 Beyond Glaucoma Into Big Eye Disease Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. uses SBI-200 to diversify beyond glaucoma into uveitis, dry eye, macular degeneration, and diabetic retinopathy, so the platform is no longer tied to one indication. That matters because dry eye affects about 16 million U.S. adults, age-related macular degeneration about 20 million, and diabetes 537 million adults worldwide in 2021.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry eye\u003c\/td\u003e\n\u003ctd\u003e16 million U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMD\u003c\/td\u003e\n\u003ctd\u003e20 million U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e537 million global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235015237897,"sku":"skye-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/skye-ansoff-matrix.webp?v=1785731701","url":"https:\/\/dcfanalyst.com\/products\/skye-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}